Project Grant R01CA297995
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$647K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
The National Cancer Institute awarded a Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) totaling $568,151 to the Regents of the University of Michigan. The grant will fund research to develop a real-time functional photoacoustic imaging platform with the capability to quantitatively evaluate prostate cancer tumor heterogeneity and microenvironment for improved prostate cancer diagnosis and prognosis. The research aims to optimize photoacoustic-nanoparticle contrast...
This federal Project Grant award of $620,521, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports an integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response. The key products and services to be delivered under this 5-year award, which commenced on January 1, 2025, include: Developing a novel hybrid cellular automata mathematical model to describe the...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to investigate the use of advanced dual-nuclei MRI techniques, including proton-based diffusion-relaxation correlation spectrum imaging (DR-CSI) and sodium imaging, to non-invasively differentiate between recurrent brain metastasis (RBM) and radiation necrosis (RN) in brain metastases patients. The $382,449 award will support the development and validation of these MRI...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $452,540 to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will enable real-time monitoring of endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma undergoing bispecific T-cell engager antibody (BiTEA) treatments. The goal is to better understand mechanisms of therapy...
This Project Grant award, funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports the development of an AI-assisted quantitative photon-counting-detector CT imaging protocol for cytogenetic risk prediction and treatment response assessment in multiple myeloma. The key products and services to be delivered under this $546,874 award, with a...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $159,803 to the Regents of the University of Michigan to incorporate emerging genomic, transcriptomic, epigenomic, and proteomic technologies for the analysis of advanced, rare, and pediatric cancers. The project aims to translate these new analytical approaches into clinically actionable information through the development of reportable test results in the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $458,698 to the Regents of the University of Michigan to conduct research aimed at understanding the fundamental biological mechanisms underlying acute myeloid leukemia (AML) relapse. The research will focus on identifying novel gene drivers that confer therapy resistance and contribute to the competitive regrowth of leukemic cells after initial treatment, which is a major barrier...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...
The National Cancer Institute (NCI) awarded a $674,440 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Miami to conduct research aimed at differentiating benign and malignant multiple myeloma precursor conditions. The 5-year project, beginning February 2025, will leverage single-cell whole genome sequencing and immune microenvironment analysis to comprehensively define the clinical impact of key myeloma genomic and immune events. This research seeks to overcome...
This federal Project Grant award of $677,801, provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research at Yale University to develop a non-invasive magnetic resonance imaging (MRI) technique called Deuterium Metabolic Imaging (DMI) for detecting and monitoring disease progression in patients with glioblastoma, an aggressive brain tumor. The key objectives are to: 1) validate the specificity of DMI for detecting active...